Development of tivanisiran, a topical siRNA designed to treat dry eye disease

Bleau, Anne-Marie; Ruz, Veronica; González, Victoria; Martínez, Tamara; Vargas, Beatriz; Jiménez, Ana I.

doi:10.15761/icm.1000124

Cited by 4 publications

(1 citation statement)

References 11 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the moment, only Tivanisiran, former SYL1001, a small interfering RNA (siRNA) targeting TRPV1 is still under development for dry eye disease, where the nociceptive channel is thought to be involved in ocular pain and inflammation (64). So far, topical administration of SYL1001 was shown effective without tolerability issues (65,66).…”

Section: In Addition Johnson and Johnson Pharmaceutical Research And Development Developed A Trpv1mentioning

confidence: 99%

TRP Channel Cooperation for Nociception: Therapeutic Opportunities

Bamps

Vriens

Hoon

et al. 2021

Annu. Rev. Pharmacol. Toxicol.

View full text Add to dashboard Cite

Chronic pain treatment remains a sore challenge, and in our aging society, the number of patients reporting inadequate pain relief continues to grow. Current treatment options all have their drawbacks, including limited efficacy and the propensity of abuse and addiction; the latter is exemplified by the ongoing opioid crisis. Extensive research in the last few decades has focused on mechanisms underlying chronic pain states, thereby producing attractive opportunities for novel, effective and safe pharmaceutical interventions. Members of the transient receptor potential (TRP) ion channel family represent innovative targets to tackle pain sensation at the root. Three TRP channels, TRPV1, TRPM3, and TRPA1, are of particular interest, as they were identified as sensors of chemical- and heat-induced pain in nociceptor neurons. This review summarizes the knowledge regarding TRP channel–based pain therapies, including the bumpy road of the clinical development of TRPV1 antagonists, the current status of TRPA1 antagonists, and the future potential of targeting TRPM3. Expected final online publication date for the Annual Review of Pharmacology and Toxicology, Volume 61 is January 7, 2021. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

show abstract

Section: In Addition Johnson and Johnson Pharmaceutical Research And Development Developed A Trpv1mentioning

confidence: 99%